Enhancing biodistribution of therapeutic enzymes in vivo by modulating surface coating and concentration of ICAM-1-targeted nanocarriers

Journal of Biomedical Nanotechnology

Volumn 10, Issue 2, 2014, Pages 345-354

  Hsu, Janet ^a   Bhowmick, Tridib ^b   Burks, Scott R ^c   Kao, Joseph P Y ^c   Muro, Silvia ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Carrier bulk concentration; Enzyme delivery; ICAM 1 Targeted nanocarriers; Lysosomal fabry disease; Targeting surface density

Indexed keywords

CARRIER BULK-CONCENTRATION; ENZYME DELIVERY; FABRY DISEASE; NANO-CARRIERS; TARGETING SURFACE-DENSITY;

BLOOD; CARRIER CONCENTRATION; CELL ADHESION; PROTEINS; TISSUE;

ENZYMES;

ALPHA GLUCOSIDASE; CELL SURFACE MARKER; FLUORESCEIN ISOTHIOCYANATE; INTERCELLULAR ADHESION MOLECULE 1; LYSOSOME ENZYME; NANOCARRIER; NANOCOATING; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BRAIN; CONTROLLED STUDY; ENZYME REPLACEMENT; FLUORESCENCE; HEART; KIDNEY; LIVER; LUNG; MOUSE; NONHUMAN; SPLEEN; TISSUE DISTRIBUTION;

ALPHA-GALACTOSIDASE; ANIMALS; ANTIBODY SPECIFICITY; COATED MATERIALS, BIOCOMPATIBLE; DRUG CARRIERS; FLUORESCEIN-5-ISOTHIOCYANATE; INTERCELLULAR ADHESION MOLECULE-1; MICE; MICE, INBRED C57BL; NANOPARTICLES; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 84893157340     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1718     Document Type: Article

References (32)

1. R. Solaro, F. Chiellini, and A. Battisti, Targeted delivery of protein drugs by nanocarriers. Materials 3, 1928 (2010).
2. V. P. Torchilin, Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 58, 1532 (2006).
3. A. H. Futerman and G. van Meer, The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 5, 554 (2004).
4. E. F. Neufeld, The uptake of enzymes into lysosomes: An overview. Birth Defects Orig. Artic. Ser. 16, 77 (1980).
5. D. A. Brooks, Immune response to enzyme replacement therapy in lysosomal storage disorder patients and animal models. Mol. Genet. Metab. 68, 268 (1999).
6. R. Dhami and E. H. Schuchman, Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages: Implications for Niemann-Pick disease enzyme replacement therapy. J. Biol. Chem. 279, 1526 (2004).
7. S. Muro, Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders. Drug Delivery and Translational Research 2, 169 (2012).
8. B. Sun, S. Li, A. Bird, H. Yi, A. Kemper, B. L. Thurberg, and D. D. Koeberl, Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine pompe disease. J. Gene Med. 12, 881 (2010).
9. W. R. Wilcox, G. E. Linthorst, D. P. Germain, U. Feldt-Rasmussen, S. Waldek, S. M. Richards, D. Beitner-Johnson, M. Cizmarik, J. A. Cole, W. Kingma, and D. G. Warnock, Anti-alpha-galactosidase a antibody response to agalsidase beta treatment: Data from the fabry registry. Mol. Genet. Metab. 105, 443 (2012).
10. J. Hsu and S. Muro,Nanomedicine and drug delivery strategies for treatment of genetic diseases, Human Genetic Diseases, edited by Plaseska-Karanfilska D., Ed.Plaseska-Karanfilska D. S, InTech., Rijeka, Croatia (2011), pp. 241.
11. S. Muro, New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2, 189 (2010).
12. S. D. Marlin and T. A. Springer, Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 51, 813 (1987).
13. S. Muro, Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1, Endothelial Biomedicine, edited by Aird W. C., Ed. Aird W. C.s, Cambridge University Press, New York (2007), pp. 1058.
14. T. Bhowmick, J. Hsu, R. Dhami, S. R. Burks, J. P. Y. Kao, E. H. Schuchman, and S. Muro, ICAM-1-targeted nanocarriers provide efficient targeting, transport across the BBB, and uniform distribution and effects of therapeutic enzymes in the brain. In Controlled Release Society, Journal of Controlled Release, National Harbor, Maryland, U.S.A., (2011), p 34.
15. C. Garnacho, R. Dhami, E. Simone, T. Dziubla, J. Leferovich, E. H. Schuchman, V. Muzykantov, and S. Muro, Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J. Pharmacol. Exp. Ther. 325, 400 (2008).
16. R. Ghaffarian, T. Bhowmick, and S. Muro, Transport of nanocarriers across gastrointestinal epithelial cells by a new transcellular route induced by targeting ICAM-1. J. Control. Release 163, 25 (2012).
17. J. Hsu, L. Northrup, T. Bhowmick, and S. Muro, Enhanced delivery of alpha-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: Comparative performance of a strategy for three distinct lysosomal storage disorders. Nanomedicine 8, 731 (2012).
18. J. Hsu, D. Serrano, T. Bhowmick, K. Kumar, Y. Shen, Y. C. Kuo, C. Garnacho, and S. Muro, Enhanced endothelial delivery and biochemical effects of alpha-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease. J. Control. Release 149, 323 (2011).
19. S. Muro, E. H. Schuchman, and V. R. Muzykantov, Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol. Ther. 13, 135 (2006).
20. I. T. Papademetriou, C. Garnacho, E. H. Schuchman, and S. Muro, In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors. Biomaterials 34, 3459 (2013).
21. J. Papademetriou, C. Garnacho, D. Serrano, T. Bhowmick, E. H. Schuchman, and S. Muro, Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor. J. Inherit. Metab. Dis. 36, 467 (2013).
22. A. J. Calderon, T. Bhowmick, J. Leferovich, B. Burman, B. Pichette, V. Muzykantov, D. M. Eckmann, and S. Muro, Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers. J. Control. Release 150, 37 (2011).
23. M. Gary-Bobo, P. Nirde, A. Jeanjean, A. Morere, and M. Garcia, Mannose 6-phosphate receptor targeting and its applications in human diseases. Curr. Med. Chem. 14, 2945 (2007).
24. J. M. Saul, A. V. Annapragada, and R. V. Bellamkonda, A dualligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J. Control. Release 114, 277 (2006).
25. R. J. Desnick, Y. A. Ioannou, and C. M. Eng, α-Galactosidase a deficiency: Fabry disease, The Metabolic and Molecular Bases of Inherited Disease, edited by C. Scriver, A. Beaudet, W. Sly, D. Valle, B. Childs, K. Kinzler, B. Vogelstein, and F. Bunz, McGraw-Hill (2001), Vol. 3, p. 3733.
26. J. L. Park, S. E. Whitesall, L. G. D'Alecy, L. Shu, and J. A. Shayman, Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect. Clin. Exp. Pharmacol. Physiol. 35, 1156 (2008).
27. R. J. Desnick, Enzyme replacement therapy for fabry disease: Lessons from two alpha-galactosidase a orphan products and one FDA approval. Expert Opin. Biol. Ther. 4, 1167 (2004).
28. A. M. Jevnikar, R. P. Wuthrich, F. Takei, H. W. Xu, D. C. Brennan, L. H. Glimcher, and V. E. Rubin-Kelley, Differing regulation and function of ICAM-1 and class II antigens on renal tubular cells. Kidney Int. 38, 417 (1990).
29. S. Muro, T. Dziubla, W. Qiu, J. Leferovich, X. Cui, E. Berk, and V. R. Muzykantov, Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J. Pharmacol. Exp. Ther. 317, 1161 (2006).
30. R. Rossin, S. Muro, M. J. Welch, V. R. Muzykantov, and D. P. Schuster, In vivo imaging of 64Cu-labeled polymer nanoparticles targeted to the lung endothelium. J. Nucl. Med. 49, 103 (2008).
31. Y. Matsumura and H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387 (1986).
32. S. Muro, C. Garnacho, J. A. Champion, J. Leferovich, C. Gajewski, E. H. Schuchman, S. Mitragotri, and V. R. Muzykantov, Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther 16, 1450 (2008).